|
**Overview**: Leukemia Customized 10 Markers Panel**Introduction**: The Leukemia Customized 10 Markers Panel is a diagnostic tool designed for customized leukemia screening using whole blood or bone marrow samples. In India, personalized flow panels are increasingly used in complex or atypical leukemias to target specific markers based on morphology or prior results, optimizing resource use in high-volume labs. High morbidity from generic testing in rural/low-SES patients with cytopenias, limited customization leading to inconclusive results or delayed therapy. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 14 user-selected markers (e.g., CD3, CD4, CD19, CD34, CD13, CD33, etc.) over 1-2 days with high accuracy, valuable for tailored immunophenotyping in suspected leukemia or lymphoma. This diagnostic falls under leukemia screening and targets patients with atypical presentation or prior inconclusive tests, addressing accurate detection to guide precise therapy. With elevated morbidity due to under-customization, the test supports public health efforts by enabling flexible marker analysis and improving diagnostic yield. Its blood/bone marrow-based approach ensures reliable targeted profiling.**Other Names**: Leuk Custom Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Customized flow panels standard; in India, used in advanced hematology labs.**Purpose**: The test assesses 14 parameters including custom markers to guide customized leukemia screening, target specific antigens, inform diagnosis.**Test Parameters**: 1â€"14. Custom Markers (CD3, CD4, CD19, CD34, etc.).**Pretest Condition**: No fasting required; patients should have cytopenias or blasts.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow/PCR).**Medical History**: Patients should provide details on prior results, suspected subtype.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of inconclusive diagnosis including delayed therapy, benefits of customization, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Targeted marker expression confirms suspected diagnosis, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Full panel or NGS for confirmation.**Test Limitations**: Marker selection critical; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
